These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 2677242

  • 21. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
    Da Prada M, Burkard WP.
    Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
    [Abstract] [Full Text] [Related]

  • 22. Pharmacology of moclobemide.
    Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, Martin JR, Moreau JL, Richards JG, Schaffner R.
    Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
    [Abstract] [Full Text] [Related]

  • 23. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors.
    Delini-Stula A, Radeke E, Waldmeier PC.
    Psychopharmacol Ser; 1988; 5():147-58. PubMed ID: 3045798
    [Abstract] [Full Text] [Related]

  • 24. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR, Firkusny L, Schick C, Antonin KH, Nilsson E, Schulz R, Schwenk M, Wollmann H.
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [Abstract] [Full Text] [Related]

  • 25. Short-lasting and reversible inhibition of monoamine oxidase-A by moclobemide.
    Da Prada M, Kettler R, Keller HH, Burkard WP.
    Acta Psychiatr Scand Suppl; 1990 Mar; 360():103-5. PubMed ID: 2248059
    [Abstract] [Full Text] [Related]

  • 26. The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo.
    Waldmeier PC, Stöcklin K.
    Eur J Pharmacol; 1989 Oct 10; 169(2-3):197-204. PubMed ID: 2806381
    [Abstract] [Full Text] [Related]

  • 27. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC.
    J Pharmacol Exp Ther; 1989 Jan 10; 248(1):391-9. PubMed ID: 2913284
    [Abstract] [Full Text] [Related]

  • 28. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.
    Da Prada M, Zürcher G, Wüthrich I, Haefely WE.
    J Neural Transm Suppl; 1988 Jan 10; 26():31-56. PubMed ID: 3283290
    [Abstract] [Full Text] [Related]

  • 29. Some in vitro effects of moclobemide and other MAO inhibitors on responses to sympathomimetic amines.
    Callingham BA, Ovens RS.
    J Neural Transm Suppl; 1988 Jan 10; 26():17-29. PubMed ID: 3283289
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A.
    Ametamey SM, Beer HF, Guenther I, Antonini A, Leenders KL, Waldmeier PC, Schubiger PA.
    Nucl Med Biol; 1996 Apr 10; 23(3):229-34. PubMed ID: 8782230
    [Abstract] [Full Text] [Related]

  • 36. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.
    Fitton A, Faulds D, Goa KL.
    Drugs; 1992 Apr 10; 43(4):561-96. PubMed ID: 1377119
    [Abstract] [Full Text] [Related]

  • 37. Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies.
    Callingham BA.
    Br J Psychiatry Suppl; 1989 Oct 10; (6):53-60. PubMed ID: 2619973
    [Abstract] [Full Text] [Related]

  • 38. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G, Classen W, Sofic E, Becker T, Riederer P, Lesch KP, Struck M, Beckmann H.
    J Neural Transm Suppl; 1990 Oct 10; 32():189-95. PubMed ID: 2089089
    [Abstract] [Full Text] [Related]

  • 39. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul 10; 18(4):793-802. PubMed ID: 7938567
    [Abstract] [Full Text] [Related]

  • 40. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
    Möller HJ, Wendt G, Waldmeier P.
    Pharmacopsychiatry; 1991 Mar 10; 24(2):50-4. PubMed ID: 1852792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.